Therapeutic Outcomes and Electrophysiological Biomarkers in Anti-Myelin-Associated Glycoprotein Neuropathy: A Multicenter Cohort Study in South Koreaopen access
- Authors
- Min, Young Gi; Han, Hee-Jo; Shin, Ha Young; Baek, Jong-Gyu; Kim, Jun -Soon; Park, Kyung-Seok; Baek, Seol-Hee; Yoo, Ilhan; Huh, So -Young; Kwon, Young Nam; Choi, Seok-Jin; Kim, Sung -Min; Hong, Yoon-Ho; Sung, Jung-Joon
- Issue Date
- Jan-2024
- Publisher
- 대한신경과학회
- Keywords
- anti-MAG neuropathy; immunotherapy; efficacy; biomarker; nerve conduction study
- Citation
- Journal of Clinical Neurology, v.20, no.1, pp 50 - 58
- Pages
- 9
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Journal of Clinical Neurology
- Volume
- 20
- Number
- 1
- Start Page
- 50
- End Page
- 58
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/65443
- DOI
- 10.3988/jcn.2023.0127
- ISSN
- 1738-6586
2005-5013
- Abstract
- Background and Purpose Unlike other immune-mediated neuropathies, anti-myelin -as-sociated glycoprotein (MAG) neuropathy is often refractory to immunotherapy. It is necessary to compare the relative efficacies of various immunotherapies and develop objective biomark-ers in order to optimize its clinical management.Methods This study recruited 91 patients with high anti-MAG antibody titers from 7 tertiary hospitals in South Korea. We analyzed the baseline characteristics, therapeutic outcomes, and nerve conduction study (NCS) findings of 68 patients and excluded 23 false positive cases.Results The rate of positive responses to treatment was highest using zanubrutinib (50%) and rituximab (36.4%), followed by corticosteroids (16.7%), immunosuppressants (9.5%), in-travenous immunoglobulin (5%), and plasma exchange (0%). Disability and weakness were significantly associated with multiple NCS parameters at the time of diagnosis, especially dis-tal compound muscle action potential (CMAP) amplitudes. Moreover, the longitudinal tra-jectory of the average CMAP amplitudes paralleled the clinical courses, with a 16.2 percentile decrease as an optimal cutoff for predicting a clinical exacerbation (area under the receiver op-erating characteristic curve=0.792).Conclusions Our study supports the use of NCS as an objective marker for estimating disease burden and tracking clinical changes in patients with anti-MAG neuropathy. We have described the beneficial effects of rituximab and a new drug, zanubrutinib, compared with conventional immunotherapies.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 5. Others > ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.